1.
Targeting cellular senescence prevents age-related bone loss in mice
by Farr, Joshua N
Nature medicine, 2017-09, Vol.23 (9), p.1072-1079
2.
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
by Xian, Lingling
Nature medicine, 2012-07, Vol.18 (7), p.1095-1101
3.
Targeting skeletal endothelium to ameliorate bone loss
by Xu, Ren
Nature medicine, 2018-06, Vol.24 (6), p.823-833
4.
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis
by Ishii, Masaru
Nature, 2009-03-26, Vol.458 (7237), p.524-528
5.
Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect
by Ortuño, María José
Nature medicine, 2016-10, Vol.22 (10), p.1170-1179
6.
Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone
by Cui, Zhuang Zhuang
Annals of the rheumatic diseases, 2015-10-15, Vol.75 (9), p.1714-1721
7.
Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone
by Merzaban, Jasmeen S
Nature medicine, 2008-02, Vol.14 (2), p.181-187
8.
Bone tissue engineering and regeneration: from discovery to the clinic--an overview
by O'Keefe, Regis J
Tissue engineering. Part B, Reviews, 2011-12, Vol.17 (6), p.389-392
9.
Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial
by Brixen, Kim
The journal of clinical endocrinology and metabolism, 2013-02, Vol.98 (2), p.571-580
10.
Role of ERα in the Effect of Estradiol on Cancellous and Cortical Femoral Bone in Growing Female Mice
by Vinel, A
Endocrinology (Philadelphia), 2016-06, Vol.157 (6), p.2533-2544
11.
Harnessing and modulating inflammation in strategies for bone regeneration
by Mountziaris, Paschalia M
Tissue engineering. Part B, Reviews, 2011-12, Vol.17 (6), p.393-402
12.
Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome
by Sakka, Sophia
The journal of clinical endocrinology and metabolism, 2017-11, Vol.102 (11), p.4163-4172
13.
Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone
by Lazarenko, Oxana P
Endocrinology (Philadelphia), 2007-06, Vol.148 (6), p.2669-2680
14.
Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody
by Li, Xiaodong
Endocrinology (Philadelphia), 2014-12, Vol.155 (12), p.4785-4797
15.
Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice
by Xiao, Liping
Endocrinology (Philadelphia), 2017-10-01, Vol.158 (10), p.3629-3646
16.
Effects of Estrogen on Bone mRNA Levels of Sclerostin and Other Genes Relevant to Bone Metabolism in Postmenopausal Women
by Fujita, Koji
The journal of clinical endocrinology and metabolism, 2014-01, Vol.99 (1), p.E81-E88
17.
Effect of Polycaprolactone Scaffold Permeability on Bone Regeneration In Vivo
by Mitsak, Anna G.
Tissue engineering. Part A, 2011-07-01, Vol.17 (13-14), p.1831-1839
18.
Effects of Parathyroid Hormone on Bone Mass, Bone Strength, and Bone Regeneration in Male Rats With Type 2 Diabetes Mellitus
by Hamann, Christine
Endocrinology (Philadelphia), 2014-04, Vol.155 (4), p.1197-1206
19.
Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss
by Krishnamurthy, Akilan Akilan
Annals of the rheumatic diseases, 2015-11-26, Vol.75 (4), p.721-729
20.
Insulin-Like Growth Factor-Independent Effects of Growth Hormone on Growth Plate Chondrogenesis and Longitudinal Bone Growth
by Wu, Shufang
Endocrinology (Philadelphia), 2015-07, Vol.156 (7), p.2541-2551
